APXENTA 30MG

Description

Apxenta 30mg Tablet is a therapeutic agent used in the management of moderate to severe plaque psoriasis and psoriatic arthritis. Plaque psoriasis is characterized by red, scaly patches on the skin, while psoriatic arthritis involves joint inflammation associated with psoriasis. Apxenta, containing Apremilast, works by inhibiting the enzyme phosphodiesterase 4 (PDE4), leading to a reduction in the production of pro-inflammatory mediators. This mechanism helps alleviate the symptoms of these conditions.

Dosage and Administration:

The dosage of Apxenta is individualized based on the patient’s condition and response to treatment. It is typically administered orally, with or without food. The tablet should be swallowed whole and not crushed or chewed. Patients are advised to follow the dosing schedule prescribed by their healthcare provider.

Common Side Effects:

Patients may experience side effects such as nausea, diarrhea, vomiting, headache, and upper respiratory tract infections. These side effects are generally mild and may resolve with continued use. However, if they persist or worsen, medical attention should be sought.

Precautions:

• Weight Monitoring: Apxenta may cause weight loss; therefore, regular monitoring is recommended.

• Mood Changes: Patients should be monitored for signs of depression or suicidal thoughts.

• Drug Interactions: Concurrent use with certain medications, such as rifampicin, phenytoin, phenobarbital, and carbamazepine, may reduce the effectiveness of Apxenta. Consultation with a healthcare provider is essential before starting new medications.

Contraindications:

Apxenta is contraindicated in individuals with known hypersensitivity to Apremilast or any of its components. It is also not recommended for use in children and adolescents under 17 years of age.

Pregnancy and Breastfeeding:

The safety of Apxenta during pregnancy and breastfeeding has not been established. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consultation with a healthcare provider is advised.